The European Commission (EC) has granted marketing authorization to Rinvoq (upadacitinib; 15mg, once daily), from US pharma ...

Discover whether AbbVie or Sanofi holds the edge in the global immunology market and find out which stock shows more ...

AbbVie's IL-23 inhibitor Skyrizi trailed some of its rivals in its first indication psoriasis, but has leapfrogged into first place in Crohn's disease after getting approval for the new indication ...

AbbVie has picked up another indication for its JAK inhibitor Rinvoq in the EU, becoming the first approved oral therapy for ...

Wegovy and Zepbound are just the latest drug dyads to face-off in the competitive pharma market, continuing a legacy of ...

AbbVie (NYSE: ABBV) today announced that the European Commission (EC) granted marketing authorization to RINVOQ� (upadacitinib; 15 mg, once daily) for the treatment of giant cell arteritis (GCA) in ...

A growing momentum for earlier treatment of psoriasis has the potential to improve outcomes with oral therapies and biologics ...

Eli Lilly’s Omvoh became the first IL-23 drug approved in ulcerative colitis in October 2023, while AbbVie’s Skyrizi hit the scene as the first IL-23 med cleared by the FDA to treat Crohn’s ...

The findings highlight the potential benefits of newer biologics targeting IL-12, IL-23, and IL-17 while also raising ...